Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LUMINA: A Phase III, Multicenter, Sham-Controlled, Randomized, Double-Masked Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye.

NCT03711929 is registered in ClinicalTrials.gov with Santen Inc. as lead sponsor.

NCT NCT03711929
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03711929 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LUMINA: A Phase III, Multicenter, Sham-Controlled, Randomized, Double-Masked Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye.
Lead sponsor
Santen Inc.
Phase
Phase 3
Overall status
Terminated
Start date
November 19, 2018
Completion date
June 14, 2022
Enrollment
145 (actual)
Sites
65

Conditions

As the registry lists them; a condition with its own page is linked.

non infectious uveitis